Reactions
(17)
No comment yet.
Sign up to comment
Digital health is going to need medical approval and a great UI
So far the internet of things hasn’t made much headway into patient care in the medical setting, but consumers are buying wellness devices for a variety of reasons. Will the medical world embrace that data?
The intersection of healthcare and connected devices was thrown into high relief these last few weeks as both Apple and Samsung unveiled ecosystems to take consumer health data and turn it into actionable intelligence.
But this week’s guests at the Weekly podacst at GigaOm are confident that as advanced as consumer-grade consumer grade health devices get, they won’t become something doctors are hot on for years to come — if ever.
In this week’s podcast Stacey Higginbotham discusses medical connected devices and where it may meet the consumer with Rick Valencia from Qualcomm Life. Will doctor’s prescribe our apps or devices?
Listen to the podcast at http://soundcloud.com/gigaom-internet-of-things Original article at http://gigaom.com/2014/06/09/digital-health-is-going-to-need-medical-approval-and-a-great-ui/ ;
Vigisys's curator insight,
June 15, 2014 4:22 AM
Un podcast intéressant qui évoque les freins à l'utilisation médicale des objets connectés. On y évoque le besoin de valider les usages avec des études cliniques et d'adapter les interfaces à un usage professionnel. Que du bon sens !
Drug Companies Could Use EHR Systems for Targeted Marketing #pharma
Pharmaceutical companies increasingly are using electronic health records to analyze patient data and market their products to consumers and physicians through advertisements and email campaigns.
Electronic health record systems could be used by pharmaceutical companies to market their products to physicians and consumers,Reuters reports.
Pharmaceutical companies historically have gathered patients' de-identified data from insurers, pharmacies and public records to improve their marketing strategies.
However, drug companies can collect and analyze data through EHR systems and use that information to reach out to consumers and doctors.
Health Risk Assessments Are A Powerful Component of Population Health Management
Health Risk Assessments (HRAs) are a powerful component of population health management strategies for healthcare organizations.
kamagra-hilfe.com's curator insight,
March 10, 2014 5:19 AM
potenzmittel rezeptfrei
http://kamagra-hilfe.com/
Sherri Altman's curator insight,
September 15, 2014 9:53 PM
Curious how these metrics compare to the HRA we have deployed to our consumers. As an organization we have decided to target key chronic conditions to help reduce costs. What other prevention programs could or should we be considering to assist our members?
Maximizing the Use of YouTube in #Pharma Communications #hcsm
The scope of YouTube is staggering. In 2008, YouTube contained over 70 million videos, published by over 200,000 creators. Every minute, 13 hours of video are uploaded to YouTube. In January 2009, 147 million U.S. Internet users watched an average of 101 videos per person on the site.
The population that uses YouTube is highly varied and skews slightly older than other social networking sites, with the average age of a video viewer being nearly 27. The uses of YouTube are also highly varied, and business marketing is prominent among them.
Numerous brands and television networks have established channels, as have most politicians and celebrities with their own unique designs and constantly updated content. Some of the most highly views clips on YouTube are branded content, but they go beyond a simple rehash of commercials on TV (“The Epic Split feat. Van Damme” is one recent example that springs to mind). It’s no secret why brands are fond of YouTube – it has the ability to connect with consumers on an emotional level through the power of story and video.
Read more: http://social.eyeforpharma.com/column/maximizing-use-youtube-pharma-communications
Online Healthcare Marketing: What Works in a Post-Google Hummingbird World #hcsm
Simply maintaining a web presence isn’t enough. In the post-Google Hummingbird era, where conversational search becomes the norm, what matters most is context.
You don’t need any of those cookie-cutter approaches to getting found online. What you need is an effective inbound marketing strategy where context rules. Premier marketing agency HubSpot has already warned us that context is the future of inbound marketing. It's about time we take this seriously.
But what do we really know about it? And how, exactly, does this idea apply to online healthcare marketing? Here’s a quick look at some strategies that work.
Online Profile Management for Oncologists
An understanding of Online Profile Management for Oncologists, with an Indian perspective.
Covers Digitally Aware Patients and Social Networks, The Need for Online Profile Management, an understanding of Local Reputation vs Global Reputation, Tips for How to do it while avoiding the traps and describing techniques for Maximizing Online Exposure for Oncologists
For Some Cancer Patients, Personalized Medicine Has Arrived
New tools for analyzing genes are allowing doctors to personalize treatment for some lung cancer patients.
Imagine your doctor being able to scan your DNA from a biopsy and pinpoint the medicine that will work best for you. This type of high-tech approach is a clinical reality for advanced lung cancer at The Ohio State Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The technology, known as next generation "multiplex" gene sequencing, analyzes 50-plus genes in DNA extracted from a tumor biopsy for particular genetic mutations.
Previous technology required pathologists to analyze one mutation per tube in a sequencing reaction, but next-generation genome sequencing assesses more than 2,500 mutations in a single reaction.
Knowing which mutations are present in lung tumors can help doctors tailor a patient's treatment to the unique genetic features present in his or her cancer cells.
The knowledge can also help in the development of new drugs that target previously unrecognized gene mutations in lung tumors. I often compare these genes to the gas pedal in a car — when activated, these genes make the cancer grow. By breaking the linkage between the gas pedal and the motor (or interfering with these "driver" mutations) with specific targeted drugs, doctors can stop this growth and often make the cancer shrink.
That's especially important in lung cancer because the majority of patients with this disease are diagnosed in the later stages, meaning it's important to start effective therapies quickly.
For example, a patient could be given a standard chemotherapy and expect a 25- to 30- percent response rate/shrinkage of a tumor. But if the treatment team knows that a patient has a mutation in a gene called EGFR, we can offer him or her a pill (erlotinib and afatinib are approved for this use in the United States), which has a 75-percent response rate and fewer side effects.
Gene sequencing is now considered the standard of care for stage-4 lung cancer patients at The OSUCCC – James and a handful of other centers across the United States — and several clinical trials evaluating molecular targeted therapies for patients with stage-3 lung cancers will soon start at The OSUCCC – James.
Lung cancer remains the number one cause of cancer death in the United States, and in the world, among both men and women. More than 200,000 cases are diagnosed annually in the United States. Each year during the month of November, physicians and others observe lung cancer awareness month, which sheds light on this terrible disease.
FDA Helping to Advance Treatments Tailored to Patients
Personalized medicine is the tailoring of a medical treatment to the individual characteristics, needs and preferences of a patient. Many recent advances involve using a patient's genetic information to guide his or her treatment.
Developing a truly personalized approach to patient care will require fundamental advances in the understanding of the biological, anatomical and physiological mechanisms that underlie disease, and how they are affected by environmental, genetic, social and cultural factors.
To describe its unique responsibilities and its efforts in facilitating the advancement of personalized medicine, the Food and Drug Administration (FDA) has released a new report entitled "Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development
FDA's commitment to personalized medicine dovetails with its focus on advancing regulatory science, which is the science of developing new tools, standards and approaches to assess the safety, effectiveness, quality and performance of FDA-regulated products.
Here are some examples from the report of how FDA is using regulatory science to help speed the development of promising new personalized medicine therapies.
Virtual patient: Advances in medical imaging and the power of computers to create virtual, anatomically correct models of the human body have enabled the use of patient-specific computer simulations in clinical practice and medical device development. This has facilitated the creation of personalized, custom-built medical devices. FDA's Center for Devices and Radiological Health (CDRH) is developing a publicly available digital library of such models and simulations. This space for collaboration and sharing will help advance the personalization of medical device development and use.
Clinical Trial Designs and Methods: FDA is working to refine clinical trial design and statistical methods of analysis to address issues that often arise in the development of targeted therapeutics. The agency is also looking specifically at clinical trials for the development of cancer drugs. For example, FDA is participating in the "I-SPY 2 Trial," a groundbreaking clinical trial model that will help scientists quickly test the most promising drugs in development for women with rapidly growing breast cancers.
Biology of cancer: FDA's National Center for Toxicological Research (NCTR) conducts research to improve the understanding of cancer's underlying biology. A research project focused on the KRAS oncogene, for example, established that many tumors carry subpopulations of KRAS mutant cells, which can contribute to an acquired resistance to some cancer treatments.
Identification of genetic risk factors for vaccine reactions: FDA's Center for Biologics Evaluation and Research is involved in research collaborations that focus on identifying genetic risk factors associated with negative reactions to vaccines.
Genetics and cardiovascular risk: In collaboration with researchers at the University of Maryland, scientists at NCTR are conducting research to identify genetic factors that interact with common lifestyle factors—such as diet and drug exposure—to contribute to cardiovascular disease.
Personalized medicine for heart devices: Researchers at CDRH have made major advances in understanding the underlying biology of heart disease. They have used new methods to analyze electrocardiograms to identify the causes of heart disease and to predict which patients will benefit from specific cardiovascular treatments. These new methods are being used by outside research groups and may be used to design more efficient clinical trials in the future.
more at the original: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm372427.htm
Joel Finkle's curator insight,
November 25, 2014 10:33 AM
New FDA report on personalized medicine. We're not quite to the home "autodoc" but more treatments will be tailored to each patient's genome, for greater safety, efficacy, and probably cost.
Interest in medical uses for Android platform surpasses iPhone
Searches for android medical recently surpassed searches for iPhone medical according to Google Trends analysis.
The Apple iPhone started as the first dominant smartphone, but Android operating system smartphones are now growing in number and claiming an increasingly large share of the market.
This Google Trends analysis below shows the relatively recent emergence of Android medical as an equal if not leading medical device in Google search. The take home message for app developers is to not ignore the Android operating system when planning and producing medical apps. Search interest in iPhone and iPad medical still remains high. Google Trends is a promising tool for continued monitoring of trends and geographic regional patterns in medical app device interest.
The screen shot for the first comparison is shown below with iPhone medical plotted in blue and Android medical plotted in red. Several noteworthy findings can be seen in this comparison. First, iPhone medical clearly emerges as the earliest device with a nearly two year period before Android medical. Second, the iPhone medical keyword search peaked in early 2012. It is trending downward since that time. Third, Google Trends shows Android medical search terms recently equaling and then surpassing iPhone medical searches.
In the second screen shot, the Google Trends forecast function shows expected trends in searches for the next few months. The forecast lines for the next six months show a trend for increasing Android medical searches with a stagnant trend for iPhone medical searches.
In the third screen shot, Windows medical search finally appears on the radar in 2013, over four years after iPhone medical. The number of searches is relatively small in comparison to both iPhone and Android medical searches.
Like the iPhone, the iPad emerged as the early leader in tablets. In the final screen shot, iPad medical searches in 2010 shows a significant upward trend through 2011-2012. There appears, however, to be a decrease in iPad medical searches over the last year.
Interestingly, the regional distribution of trends by devices shows a predominance of iPhone medical search interest in the United States, Australia, Canada and the United Kingdom. In contrast, the highest regional trend for Android medical search comes from Pakistan, the Philippines and India.
Report says mHealth sensor market will grow 70% annually -- but what about slow adoption?
A new report estimates the market for sensors and mobile health apps will grow to $5.6 million by 2017. But how can that be if the adoption rate has been flat?
Best Doctors's curator insight,
April 29, 2013 4:38 PM
Medical apps: undreds of companies are making them, but who is using them?
